Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Studies on the structural abnormality of fibrinogen Paris I.
M W Mosesson, … , D L Amrani, D Ménaché
M W Mosesson, … , D L Amrani, D Ménaché
Published March 1, 1976
Citation Information: J Clin Invest. 1976;57(3):782-790. https://doi.org/10.1172/JCI108337.
View: Text | PDF
Research Article

Studies on the structural abnormality of fibrinogen Paris I.

  • Text
  • PDF
Abstract

The structural properties of an inherited fibrinogen abnormality designated fibrinogen Paris I were investigated. Dodecyl sulfate gel electrophoresis of unreduced samples revealed no discernible differences in molecular weight from normal; this implied that in fibrinogen Paris I, the normal fibrinogen architecture of six covalently linked chains per molecule is preserved. Examination of dithiothreitol reduced samples before and after treatment with Reptilase or thrombin revealed that the Aalpha- and Bbeta-chains could release the A and B peptides, respectively. A mutant chain (mol wt 52,500, termed gammaParis I) which replaces a large proportion of gamma-chains (mol wt 49,400) was shown, like normal gamma-chains, to lack thrombin- and Reptilase-sensitive sites. The gamma-chains and alpha-chains of Paris I fibrin underwent Factor XIIIa-catalyzed cross-linking slowly; this behavior was not attributable to an intrinsic abnormality of these chains themselves but rather to the inhibitory effect of the mutant gammaParis I chains on this process. Results of DEAE-cellulose gradient elution chromatography of Paris I fibrinogen preparations revealed the presence of small amounts of normal fibrinogen molecules and also indicated that the gammaParis I chains possessed structural overlap with gamma-chains. Unlike gamma-chains however, the gammaParis I chains did not incorporate dansylcadaverine in the prescence of Factor XIIIa, nor, as previously reported, did they undergo cross-linking. The observations indicate that the amine acceptor site found in the COOH-terminal region of the gamma-chain is either not present on the gammaParis I chain or is unavailable for cross-linking. Further support for localization of the abnormality in the COOH-terminal region of the molecule was obtained from the observation that during plasmic hydrolysis of Paris I fibrinogen, at least one unique form of core Fragment D (DParis I) was evolved, whereas Fragment E did not differ from normal.

Authors

M W Mosesson, D L Amrani, D Ménaché

×

Total citations by year

Year: 2005 2002 1998 1993 1989 1987 1984 1983 1982 1981 1980 1978 1977 1976 1968 Total
Citations: 1 1 4 1 2 2 2 2 2 2 3 2 2 1 1 28
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (28)

Title and authors Publication Year
Fibrinogen Philadelphia, a hypodysfibrinogenemia characterized by abnormal polymerization and fibrinogen hypercatabolism due to γ S378P mutation
MA Keller, J Martinez, TC Baradet, C Nagaswami, IN Chernysh, MK Borowski, S Surrey, JW Weisel
Blood 2005
Pan Vascular Medicine
P Lanzer, EJ Topol
2002
The location of the carboxy-terminal region of gamma chains in fibrinogen and fibrin D domains
MW Mosesson, KR Siebenlist, DA Meh, JS Wall, JF Hainfeld
Proceedings of the National Academy of Sciences 1998
Advances in Protein Chemistry
CM Silva, J Isgaard, MO Thorner
Advances in Protein Chemistry 1998
The location of the carboxy-terminal region of   chains in fibrinogen and fibrin D domains
MW Mosesson, KR Siebenlist, DA Meh, JS Wall, JF Hainfeld
Proceedings of the National Academy of Sciences 1998
γ-Chain Dysfibrinogenemias: Molecular Structure-Function Relationships of Naturally Occurring Mutations in the γ Chain of Human Fibrinogen
HC Côté, S T., KP Pratt
Blood 1998
A Review of the Hypercoagulable State
CS Eby
Hematology/Oncology Clinics of North America 1993
A gamma methionine-310 to threonine substitution and consequent N-glycosylation at gamma asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi
K Yamazumi, K Shimura, S Terukina, N Takahashi, M Matsuda
Journal of Clinical Investigation 1989
Fibrinogen Sevilla, a congenital dysfibrinogenemia characterized by an abnormal monomer aggregation and a defective plasmin lysis
FJ Fernández, P Noguerol, R Sosa, B Cuesta, JA Páramo, E Rocha
Clinica Chimica Acta 1989
Formation and regulation of platelet and fibrin hemostatic plug
J Hawiger
Human Pathology 1987
Two cases of dysfibrinogenemia characterized by abnormal fpb release: fibrinogen madrid I & II
M Borrell, L Vila, J Solá, I Coll, N Gómez, N González, ML Rutllant
Thrombosis Research 1987
.gamma. and .gamma.' chains of human fibrinogen are produced by alternative mRNA processing
DW Chung, EW Davie
Biochemistry 1984
Structure of the human gamma-fibrinogen gene. Alternate mRNA splicing near the 3' end of the gene produces gamma A and gamma B forms of gamma-fibrinogen
AJ Fornace, DE Cummings, CM Comeau, JA Kant, GR Crabtree
The Journal of biological chemistry 1984
Congenital Fibrinogen Abnormalities
D Ménaché
Annals of the New York Academy of Sciences 1983
CHEMICAL MODIFICATION OF FIBRINOGEN AND THE EFFECT ON FIBRIN FORMATION
Y Saito, A Shimizu, A Matsushima, Y Inada
Annals of the New York Academy of Sciences 1983
An Abnormal Inherited Fibrinogen (Fibrinogen Genova) with Delayed Fibrin Aggregation
HJ Hassan, M Orlando, GP Tonini, P Casalbore, A Sarti, E Boeri, R Giacchino, L Tentori, PG Mori
Scandinavian Journal of Haematology 1982
Fibrinogen bondy : A new case of dysfibrinogenemia. Isolation of the abnormal fibrinogen molecules
M Jandrot-Perrus, MH Aurousseau, MJ Rabiet, F Josso
Thrombosis Research 1982
Fibrinogen petoskey: Identification of a new dysfibrinogenemia characterized by altered release of fibrinopeptide A
DL Higgins, JA Penner, JA Shafer
Thrombosis Research 1981
Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-A alpha 16 by a histidyl residue. Evidence for thrombin-catalyzed hydrolysis at a histidyl residue
DL Higgins, JA Shafer
The Journal of biological chemistry 1981
Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (gamma')
C Wolfenstein-Todel, MW Mosesson
Proceedings of the National Academy of Sciences 1980
Fibrinopeptide release from fibrinogen Paris I
JS Finlayson, LA Reamer, MW Mosesson, D Menache
Thrombosis Research 1980
Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen
CW Francis, VJ Marder, SE Martin
The Journal of biological chemistry 1980
Congenital dysfibrinogenemia : Fibrinogen lille
MH Denninger, JS Finlayson, LA Reamer, A Parquet-Gernez, M Goudemand, D Menache
Thrombosis Research 1978
Human fibrinogen heterogeneities. Preparation and characterization of γ and γ′ chains
NE Stathakis, MW Mosesson, DK Galanakis, D Ménache
Thrombosis Research 1978
Dysfibrinogen�mie
FR Matthias, WH Krause, S Ganssert, K Mueller, HG Lasch
Klinische Wochenschrift 1977
Dysfibrinogen�mie: Zugleich ein neuer Fall: Dysfibrinogen�mie Gie�en III
FR Matthias, WH Krause, S Ganssert, K Mueller, HG Lasch
Klinische Wochenschrift 1977
Hydrolysis of fibrinogen Paris I by plasmin
MW Mosesson, MH Denninger, D Ménaché
Thrombosis Research 1976
Blut und Blutkrankheiten
L Heilmeyer, K Betke, KG von Boroviczény, D Busch, E Grundmann, H Heimpel, G Hoffmann, W Hunstein, W Keiderling, M Matthes, H Merker, W Müller, P Pfannenstiel
1968

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts